Earlier Alzheimer’s Treatment Delivers One-Third More Lifetime Value, USC Study Finds

A new economic analysis from the University of Southern California’s Schaeffer Center for Health Policy & Economics suggests that the timing of Alzheimer’s disease treatment may matter nearly as much as the treatment itself. The study, published October 7 in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, projects that the anti-amyloid therapy donanemab, marketed as Kisunla, could generate roughly $104,900 in lifetime social value per person when started at the point typically seen in clinical trials. If treatment begins just two years earlier, that figure rises by 32 percent to $138,300. The findings arrive at a pivotal moment for the field, as newly approved therapies that slow cognitive decline remain constrained by coverage restrictions, high costs, and the persistent difficulty of identifying eligible patients before their disease has already advanced.

The modeling effort drew on the Schaeffer Center’s U.S. Cost of Dementia Project, a federally funded initiative built to quantify the full economic burden of dementia in the United States. Using a dynamic microsimulation framework, the researchers constructed a virtual cohort closely resembling participants from the pivotal Phase 3 clinical trial of donanemab. They then compared three scenarios: receiving treatment on the schedule used in the trial, starting treatment two years earlier while still after the point at which symptoms usually emerge, and receiving no treatment at all. Crucially, the estimates capture the value of health improvements and economic benefits alone, deliberately excluding the costs of the drug itself as well as the screening and monitoring infrastructure required to deliver it.

To ground the simulation in real-world biology, the team incorporated a 29 percent slowing of disease progression for both treatment groups, matching the results donanemab achieved against placebo after 18 months in the trial. Cognitive status over each simulated lifetime was tracked using a commonly used scoring measure, calibrated with data from large national health surveys and longitudinal studies of dementia progression. This approach allowed the researchers to translate a clinical trial endpoint into something more meaningful for patients, families, and public budgets: years of life, years lived independently, and years spared from severe dementia.

The projected benefits for the trial-timing group were modest but consequential. Compared with untreated individuals, patients treated during the clinical trial were expected to live about 0.3 years longer, spend one full year less with severe dementia, gain 0.37 disability-free years, and remain living in the community for an additional 0.63 years. Those gains accumulated into the $104,900 lifetime societal value per person. Roughly half of that total, $52,300, came from improved health-related quality of life. Reductions in unpaid caregiving contributed $23,800, while medical cost offsets added $22,200, a share that accrued largely to Medicaid. On an annual basis, the model estimated that Medicaid costs fell by about $1,640 per treated patient, a 13 percent reduction.

Shifting the start of treatment two years earlier amplified every one of those measures. Because the therapy slows cognitive decline earlier in the disease course, patients spend more of their lives in earlier, more functional stages of Alzheimer’s, and the downstream savings compound. Lifetime value rose 32 percent to $138,300. The researchers also tested a scenario informed by emerging evidence suggesting that earlier treatment may produce an even stronger slowing effect, and under those assumptions the value climbed 71 percent above the clinical trial group, reaching $179,400. In other words, the window between the first subtle symptoms and a formal diagnosis may represent some of the most valuable real estate in Alzheimer’s medicine.

The study’s authors are careful to acknowledge the uncertainty inherent in evaluating therapies that have only recently entered clinical use. Because anti-amyloid treatments are so new, no one yet knows how long their benefits will persist. In a deliberately conservative scenario in which the treatment effect lasts only four years rather than for the remainder of a patient’s life, the projected lifetime value was cut roughly in half, to $49,100. Yet even under that pessimistic assumption, earlier initiation still produced 15 percent more value, at $56,400. The direction of the finding, the researchers note, is robust: whenever treatment helps, starting sooner helps more.

The economic stakes of getting this right are enormous. Alzheimer’s disease and related dementias are projected to cost the United States an estimated $818 billion in 2026, a figure expected to grow steadily as the population ages. Against that backdrop, understanding how the long-term benefits of treatment vary with the timing of initiation could inform decisions about how to expand access sustainably and where each new dollar of investment delivers the greatest impact. The analysis suggests that coverage policies and health system investments should be evaluated not only on whether patients receive therapy, but on when they receive it.

One of the most striking numbers in the study concerns the diagnosis gap itself. On average, Alzheimer’s disease is diagnosed 3.5 years after symptoms first appear, leaving a critical and largely unexploited opportunity for earlier intervention. That delay has historically been driven by the difficulty and expense of confirming the disease, which often required costly imaging or invasive procedures. But the diagnostic landscape is changing rapidly. Several blood-based biomarker tests approved by the U.S. Food and Drug Administration within the past year, along with new digital cognitive assessments, could make it substantially easier to identify Alzheimer’s in its earlier stages and connect patients to treatment while the therapies retain their greatest potential.

Lead author Jack Chapel, a USC Schaeffer scholar and assistant research professor at the USC Price School of Public Policy, framed the findings as a call to invest in the front end of the care pathway. New therapies and diagnostic tools, he noted, are making it possible to alter the course of Alzheimer’s disease, but they come with considerable costs, and the research suggests that investments in early detection could help ensure patients begin treatment when it is most likely to deliver the greatest benefit to patients and society alike. Every year between the first symptoms and a diagnosis, the study argues, is value lost for patients, their families, and the public programs that ultimately pay for dementia care.

The analysis also looks beyond today’s therapies toward the next generation. More than 150 potential Alzheimer’s treatments are currently undergoing clinical testing, and the researchers modeled what future advances might be worth if they achieve greater degrees of disease modification. A hypothetical treatment slowing progression by 50 percent would generate an estimated lifetime social value of $208,700 to $276,700 per person, depending on when treatment begins. A treatment that completely halts progression would more than double that, with estimated values ranging from $530,000 to $648,300. As therapies and diagnostics continue to improve, the authors conclude, the case for finding and treating people sooner only grows stronger, transforming early detection from a convenience into a central pillar of Alzheimer’s care and health policy.

Subject of Research: Economic modeling of the lifetime societal value of early-initiated anti-amyloid therapy for Alzheimer's disease

Article Title: Starting Alzheimer’s treatment earlier increases benefits to patients and society

Article References: Starting Alzheimer’s treatment earlier increases benefits to patients and society. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Alzheimer's disease, donanemab, anti-amyloid therapy, early detection, blood biomarkers, health economics, microsimulation, Medicaid, dementia costs, USC Schaeffer Center, clinical trials, caregiving